The Antihypertensive Effect of Remote Ischemic Conditioning (RIC-HTN).

Status Completed

Clinical Trial Summary

This study intends to further reveal the antihypertensive effect of LRIC and explore its potential mechanisms.

Clinical Trial Description

Stroke is the second-leading cause of death in the world and the leading cause of death in China. The estimated lifetime risk of stroke for those aged 25 years old and above is 24.9% worldwide and 39.3% in China. Hypertension is one of the main independent risk factors for stroke. Studies have shown that the risk of stroke increase at blood pressure (BP) above 115/75mmHg, each increase of 20mmHg in systolic blood pressure (SBP) or 10 mmHg in diastolic blood pressure (DBP) will double the risk of stroke. For those hypertensive patients without complications, each reduction of 10mmHg in SBP reduces approximately 17% risk of stroke, and each reduction of 5mmHg in DBP reduces 20%. Therefore, enhancing the primary prevention of stroke in hypertensive patients without vascular complications is important to reduce the burden of stroke in the future. However, these patients do not pay enough attention to their elevated BP and have poor compliance with antihypertensive drugs. Therefore, it is necessary to explore an economical, convenient and effective non-pharmacological therapy to control BP in order to reduce the risk of stroke. Limb remote ischemic conditioning (LRIC) triggers endogenous protective effect through transient and repeated ischemia in the limb to protect remote tissues and organs. The mechanisms of LRIC involve the regulation of autonomic nervous system, release of humoral factors, improvement of vascular endothelial function and modulation of immune/inflammatory responses, which can antagonize the pathogenesis of hypertension through multiple pathways to lead a drop in BP theoretically. This theory has been preliminarily confirmed by several small sample-size studies. Therefore, this study intends to conduct a randomized controlled trial to further reveal the antihypertensive effect of LRIC and explore its potential mechanisms. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04915313
Study type	Interventional
Source	Capital Medical University
Contact
Status	Completed
Phase	N/A
Start date	June 15, 2021
Completion date	August 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03644524` - Heat Therapy and Cardiometabolic Health in Obese Women	N/A
Completed	`NCT02551640` - Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients	N/A
Recruiting	`NCT01483430` - Effect of Ginseol Kg1 on Blood Pressure Lowering	Phase 3
Completed	`NCT01637909` - Korean Life-Style Modification Effects on Blood Pressure	N/A
Terminated	`NCT01295216` - Use of Mobile Technology to Prevent Progression of Pre-hypertension in Latin American Urban Settings	N/A
Unknown status	`NCT01308983` - Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension	Phase 4
Active, not recruiting	`NCT03596099` - Rice Vinegar as an Intervention to Lower Blood Pressure in Adults With Prehypertension and 10-year CVD Risk <10%	N/A
Completed	`NCT04326686` - Measuring Individual Responses to a Wholegrains and Nuts Intervention to Reduce Blood Pressure in Prehypertension	N/A
Completed	`NCT03898518` - The Effects of a Jump Rope Exercise Program on Body Composition and Self-efficacy in Obese Adolescent Girls	N/A
Terminated	`NCT01983462` - Vascular Dysfunction in Human Obesity Hypertension	Phase 2
Completed	`NCT01458496` - Health Coaching to Effect Lifestyle Behaviour Change	N/A
Completed	`NCT01472692` - Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure	Phase 4
Completed	`NCT03266510` - Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function	N/A
Completed	`NCT02998840` - A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure	Phase 2
Completed	`NCT01974570` - Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects	Phase 2
Completed	`NCT02326766` - Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in Prehypertensive Subjects	Phase 3
Completed	`NCT01395329` - Nebivolol and the Endothelin (ET)-1 System	Phase 4
Completed	`NCT01331486` - Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract	Phase 1
Completed	`NCT05274971` - Diet and Exercise on Ambulatory Blood Pressure	N/A
Active, not recruiting	`NCT02371317` - Stress Management for High Blood Pressure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.